Literature DB >> 24714083

Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions.

Kristy M Heppner1, Jenny Tong2.   

Abstract

Ghrelin is a 28-amino acid peptide secreted mainly from the X/A-like cells of the stomach. Ghrelin is found in circulation in both des-acyl (dAG) and acyl forms (AG). Acylation is catalyzed by the enzyme ghrelin O-acyltransferase (GOAT). AG acts on the GH secretagogue receptor (GHSR) in the CNS to promote feeding and adiposity and also acts on GHSR in the pancreas to inhibit glucose-stimulated insulin secretion. These well-described actions of AG have made it a popular target for obesity and type 2 diabetes mellitus pharmacotherapies. However, despite the lack of a cognate receptor, dAG appears to have gluco-regulatory action, which adds an additional layer of complexity to ghrelin's regulation of glucose metabolism. This review discusses the current literature on the gluco-regulatory action of the ghrelin system (dAG, AG, GHSR, and GOAT) with specific emphasis aimed toward distinguishing AG vs dAG action.
© 2014 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24714083     DOI: 10.1530/EJE-14-0183

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  21 in total

1.  Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1.

Authors:  Jenny Tong; Harold W Davis; Amalia Gastaldelli; David D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2016-04-07       Impact factor: 5.958

2.  Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans.

Authors:  Laura C Page; Amalia Gastaldelli; Sarah M Gray; David A D'Alessio; Jenny Tong
Journal:  Diabetes       Date:  2018-07-31       Impact factor: 9.461

Review 3.  Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.

Authors:  Hongjie Zhang; Jose M Garcia
Journal:  Expert Opin Pharmacother       Date:  2015-05-06       Impact factor: 3.889

Review 4.  Ghrelin's Relationship to Blood Glucose.

Authors:  Bharath K Mani; Kripa Shankar; Jeffrey M Zigman
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

5.  Acute administration of acyl, but not desacyl ghrelin, decreases blood pressure in healthy humans.

Authors:  Cecilia J Zhang; Martin Bidlingmaier; Mekibib Altaye; Laura C Page; David D'Alessio; Matthias H Tschöp; Jenny Tong
Journal:  Eur J Endocrinol       Date:  2016-11-09       Impact factor: 6.664

Review 6.  Sleep Duration and Diabetes Risk: Population Trends and Potential Mechanisms.

Authors:  Michael A Grandner; Azizi Seixas; Safal Shetty; Sundeep Shenoy
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

7.  PAX6 maintains β cell identity by repressing genes of alternative islet cell types.

Authors:  Avital Swisa; Dana Avrahami; Noa Eden; Jia Zhang; Eseye Feleke; Tehila Dahan; Yamit Cohen-Tayar; Miri Stolovich-Rain; Klaus H Kaestner; Benjamin Glaser; Ruth Ashery-Padan; Yuval Dor
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

8.  Appetite-Related Responses to Overfeeding and Longitudinal Weight Change in Obesity-Prone and Obesity-Resistant Adults.

Authors:  Tanya M Halliday; Corey A Rynders; Elizabeth Thomas; Audrey Bergouignan; Zhaoxing Pan; Elizabeth H Kealey; Marc-Andre Cornier; Daniel H Bessesen
Journal:  Obesity (Silver Spring)       Date:  2020-02       Impact factor: 5.002

Review 9.  An overview of ghrelin O-acyltransferase inhibitors: a literature and patent review for 2010-2019.

Authors:  Jacob E Moose; Katelyn A Leets; Nilamber A Mate; John D Chisholm; James L Hougland
Journal:  Expert Opin Ther Pat       Date:  2020-06-21       Impact factor: 6.674

Review 10.  Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options.

Authors:  Susan Cornell
Journal:  Ther Clin Risk Manag       Date:  2015-04-16       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.